Elevating Early Detection: Canary Speech’s Vocal Biomarker Solutions for Neurological Disorders

Canary Speech has extended its vocal biomarker offering in the neurological space with solutions for three additional conditions: mild cognitive impairment (MCI), Alzheimer’s Disease, and Parkinson’s Disease. These, together with Canary’s solution for Huntington’s Disease further establish Canary Speech’s impact in the space of vocal biomarkers for cognitive and neurodegenerative conditions.

Early Diagnosis for Cognitive Conditions

MCI and Alzheimer’s Disease are cognitive conditions. It is estimated that 12% to 18% of adults suffer from MCI, which can be an early stage of dementia, and over 6 million individuals in the US have Alzheimer’s Disease. With recent advancements in treatment programs, early diagnosis for these conditions is key. However, most early cases are missed by primary care physicians (who catch only 8% of cases of MCI).

Parkinson’s Disease is a neurodegenerative disorder that affects more than 10 million people worldwide, of which, about half are undiagnosed – with many only being diagnosed at a late stage. There is currently no cure, but early diagnosis and treatments can help prolong life and improve its quality. 

Vocal biomarkers are an inexpensive, non-invasive addition to screening and early diagnosis for those with the disease. Canary’s solution can identify patients with high accuracy.

Innovative Technology for Early Intervention

Canary Speech’s vocal biomarker technology represents a significant leap forward, surpassing existing screening methods by offering more accuracy and modeling a greater number of data points. The integration of vocal signatures, artificial intelligence, and machine learning enables the detection of mood and disease states before the presentation of observable symptoms, providing clinicians with a powerful tool for early intervention.

Key features of Canary Speech’s neurological models:

  • Proactive Screening for Clinical and Cognitive Deterioration: By meticulously modeling acoustic and linguistic features specific to each neurodegenerative condition, Canary’s models enable early detection and proactive screening for changes in a patient’s condition.
  • Clinical-Grade Home Monitoring: Canary’s technology offers clinical-grade monitoring from the comfort of patients’ homes or care facilities, reducing the need for costly and often less comfortable clinic and hospital visits.
  • Cost Reduction for Patients, Providers, and Payers: Canary Speech’s innovative approach significantly reduces the overall cost of care for elderly populations. This not only benefits patients, but also provides relief for healthcare providers and payers, making impactful care more accessible. (Learn more about our CPT codes here).
  • Non-Invasive Vocal Biomarker Data Collection: Canary’s models utilize non-invasive vocal biomarker data collection to screen for emotional wellness, mental, and physiological deterioration, ultimately minimizing hospitalizations, readmissions, and mental health struggles associated with aging populations.

Commitment to Advancing Neurological Care

Canary Speech remains committed to advancing the field of vocal biomarker technology. Its focus on developing innovative solutions for the early detection and monitoring of neurological disorders continues to expand to new conditions.

Join us in revolutionizing neurological care. Discover how Canary Speech’s cutting-edge vocal biomarker solutions can make a difference in early detection and treatment of cognitive conditions.